Literature DB >> 27502837

Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Ashwini Maratha1,2, Hugh-Owen Colhoun3, Ina Knerr1, Karen P Coss4, Peter Doran2, Eileen P Treacy5,6,7,8.   

Abstract

Classical galactosaemia is a rare disorder of carbohydrate metabolism caused by galactose-1-phosphate uridyltransferase (GALT) deficiency (EC 2.7.7.12). The disease is life threatening if left untreated in neonates and the only available treatment option is a long-term galactose restricted diet. While this is lifesaving in the neonate, complications persist in treated individuals, and the cause of these, despite early initiation of treatment, and shared GALT genotypes remain poorly understood. Systemic abnormal glycosylation has been proposed to contribute substantially to the ongoing pathophysiology. The gross N-glycosylation assembly defects observed in the untreated neonate correct over time with treatment. However, N-glycosylation processing defects persist in treated children and adults.Congenital disorders of glycosylation (CDG) are a large group of over 100 inherited disorders affecting largely N- and O-glycosylation.In this review, we compare the clinical features observed in galactosaemia with a number of predominant CDG conditions.We also summarize the N-glycosylation abnormalities, which we have described in galactosaemia adult and paediatric patients, using an automated high-throughput HILIC-UPLC analysis of galactose incorporation into serum IgG with analysis of the corresponding N-glycan gene expression patterns and the affected pathways.

Entities:  

Year:  2016        PMID: 27502837      PMCID: PMC5509556          DOI: 10.1007/8904_2016_5

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  107 in total

1.  Correction of leukocyte adhesion deficiency type II with oral fucose.

Authors:  T Marquardt; K Lühn; G Srikrishna; H H Freeze; E Harms; D Vestweber
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

2.  Inactivation of the Mgat1 gene in oocytes impairs oogenesis, but embryos lacking complex and hybrid N-glycans develop and implant.

Authors:  Shaolin Shi; Suzannah A Williams; Antti Seppo; Henry Kurniawan; Wei Chen; Zhengyi Ye; Jamey D Marth; Pamela Stanley
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

3.  Muscle glycogenosis due to phosphoglucomutase 1 deficiency.

Authors:  Tanya Stojkovic; John Vissing; François Petit; Monique Piraud; Mette C Orngreen; Grete Andersen; Kristl G Claeys; Claire Wary; Jean-Yves Hogrel; Pascal Laforêt
Journal:  N Engl J Med       Date:  2009-07-23       Impact factor: 91.245

Review 4.  Neurological aspects of human glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Annu Rev Neurosci       Date:  2015-04-02       Impact factor: 12.449

5.  Leptin levels in children and adults with classic galactosaemia.

Authors:  Ina Knerr; Karen P Coss; Peter P Doran; Joanne Hughes; Nick Wareham; Keith Burling; Eileen P Treacy
Journal:  JIMD Rep       Date:  2012-11-07

6.  GALT deficiency causes UDP-hexose deficit in human galactosemic cells.

Authors:  K Lai; S D Langley; F W Khwaja; E W Schmitt; L J Elsas
Journal:  Glycobiology       Date:  2003-01-03       Impact factor: 4.313

Review 7.  Diseases of glycosylation beyond classical congenital disorders of glycosylation.

Authors:  Thierry Hennet
Journal:  Biochim Biophys Acta       Date:  2012-02-09

8.  Long-term complications in Estonian galactosemia patients with a less strict lactose-free diet and metabolic control.

Authors:  K Krabbi; M-L Uudelepp; K Joost; R Zordania; K Õunap
Journal:  Mol Genet Metab       Date:  2011-04-02       Impact factor: 4.797

9.  Bone metabolism in galactosemia.

Authors:  B Panis; P Ph Forget; M J P G van Kroonenburgh; C Vermeer; P P Menheere; F H Nieman; M E Rubio-Gozalbo
Journal:  Bone       Date:  2004-10       Impact factor: 4.398

10.  Effects of temporary low-dose galactose supplements in children aged 5-12 y with classical galactosemia: a pilot study.

Authors:  Ina Knerr; Karen Patricia Coss; Jürgen Kratzsch; Ellen Crushell; Anne Clark; Peter Doran; Yoon Shin; Henning Stöckmann; Pauline Mary Rudd; Eileen Treacy
Journal:  Pediatr Res       Date:  2015-06-08       Impact factor: 3.756

View more
  9 in total

1.  Salubrinal enhances eIF2α phosphorylation and improves fertility in a mouse model of Classic Galactosemia.

Authors:  B Balakrishnan; A Siddiqi; J Mella; A Lupo; E Li; J Hollien; J Johnson; K Lai
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-07-27       Impact factor: 5.187

2.  Assessment of ataxia phenotype in a new mouse model of galactose-1 phosphate uridylyltransferase (GALT) deficiency.

Authors:  Wyman Chen; Rose Caston; Bijina Balakrishnan; Anwer Siddiqi; Kamalpreet Parmar; Manshu Tang; Merry Feng; Kent Lai
Journal:  J Inherit Metab Dis       Date:  2016-10-25       Impact factor: 4.982

3.  Sphingolipid depletion suppresses UPR activation and promotes galactose hypersensitivity in yeast models of classic galactosemia.

Authors:  Felipe S A Pimentel; Caio M Machado; Evandro A De-Souza; Caroline Mota Fernandes; Ana Luiza F V De-Queiroz; Guilherme F S Silva; Maurizio Del Poeta; Monica Montero-Lomeli; Claudio A Masuda
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2022-03-14       Impact factor: 6.633

Review 4.  Pathophysiology and targets for treatment in hereditary galactosemia: A systematic review of animal and cellular models.

Authors:  Minela Haskovic; Ana I Coelho; Jörgen Bierau; Jo M Vanoevelen; Laura K M Steinbusch; Luc J I Zimmermann; Eduardo Villamor-Martinez; Gerard T Berry; M Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2020-01-14       Impact factor: 4.982

5.  The natural history of classic galactosemia: lessons from the GalNet registry.

Authors:  M E Rubio-Gozalbo; M Haskovic; A M Bosch; B Burnyte; A I Coelho; D Cassiman; M L Couce; C Dawson; D Demirbas; T Derks; F Eyskens; M T Forga; S Grunewald; J Häberle; M Hochuli; A Hubert; H H Huidekoper; P Janeiro; J Kotzka; I Knerr; P Labrune; Y E Landau; J G Langendonk; D Möslinger; D Müller-Wieland; E Murphy; K Õunap; D Ramadza; I A Rivera; S Scholl-Buergi; K M Stepien; A Thijs; C Tran; R Vara; G Visser; R Vos; M de Vries; S E Waisbren; M M Welsink-Karssies; S B Wortmann; M Gautschi; E P Treacy; G T Berry
Journal:  Orphanet J Rare Dis       Date:  2019-04-27       Impact factor: 4.123

6.  Classic galactosaemia in the Greek Cypriot population: An epidemiological and molecular study.

Authors:  Rena Papachristoforou; Petros P Petrou; Hilary Sawyer; Maggie Williams; Anthi Drousiotou
Journal:  Ann Hum Genet       Date:  2019-04-17       Impact factor: 1.670

7.  Clinical and whole-exome sequencing findings in two siblings from Hani ethnic minority with congenital glycosylation disorders.

Authors:  Zhen Zhang; Ti-Long Huang; Jing Ma; Wen-Ji He; Huaiyu Gu
Journal:  BMC Med Genet       Date:  2019-11-14       Impact factor: 2.103

8.  Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents.

Authors:  Yueqin Yang; Hariprasad Vankayalapati; Manshu Tang; Yingbo Zheng; Yingri Li; Cong Ma; Kent Lai
Journal:  Molecules       Date:  2020-02-03       Impact factor: 4.411

9.  Harnessing the Power of Purple Sweet Potato Color and Myo-Inositol to Treat Classic Galactosemia.

Authors:  Synneva Hagen-Lillevik; Joshua Johnson; Anwer Siddiqi; Jes Persinger; Gillian Hale; Kent Lai
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.